| Literature DB >> 32986533 |
Brittany M Szymaniak1, Lauren A Facchini2, Veda N Giri3, Emmanuel S Antonarakis4, Tomasz M Beer5, Maria I Carlo6, Daniel C Danila6, Mallika Dhawan7, Daniel George8, Julie N Graff9, Shilpa Gupta10, Elisabeth Heath11, Celestia S Higano12, Glenn Liu13, Ana M Molina14, Channing J Paller4, Akash Patnaik15, Daniel P Petrylak16, Zachery Reichert17, Matthew B Rettig18, Charles J Ryan10, Mary-Ellen Taplin19, Jake Vinson20, Young E Whang21, Alicia K Morgans22, Heather H Cheng12, Rana R McKay23.
Abstract
Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.Entities:
Mesh:
Year: 2020 PMID: 32986533 PMCID: PMC7735040 DOI: 10.1200/OP.20.00431
Source DB: PubMed Journal: JCO Oncol Pract ISSN: 2688-1527